Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Idorsia Pharmaceutical Ltd (Idorsia), a subsidiary of Idorsia Ltd, is a biopharmaceutical company. It discovers, develops, and commercializes therapies to treat central nervous system (CNS), cardiovascular, immunological disorders, and orphan diseases. The company’s product portfolio includes Quviviq, a daridorexant, to treat insomnia; Lucerastat for Fabry disease; Daridorexant targets Pediatric insomnia; ACT-777991 treats Vitiligo; ACT-1004-1239 for Progressive multiple sclerosis; IDOR-1117-2520 targets Psoriasis; ACT-1016-0707 which treats Immune-mediated and fibrosis related disorders; and others. Idorsia's pipeline includes various drugs for the treatment of f recent-onset type 1diabetes, immune-mediated disorders, and clostridium difficile infection. The company has a vaccine platform for the development of glycoconjugate vaccines containing synthetic antigenic glycan molecules to prevent infection. Idorsia is headquartered in Allschwil, Basel-Landschaft, Switzerland.
Headquarters
Switzerland
Address
Hegenheimermattweg 91, Allschwil, Basel-Landschaft, 4123
Website
www.idorsia.com
Telephone
41 58 8440000
No of Employees
500
Industry
Pharmaceuticals and Healthcare
Idorsia Pharmaceutical Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| QUVIVIQ: Insomnia |
| TRYVIO: Systemic Hypertension |
| JERAYGO: Resistant hypertension |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In March, the company signed a deal with Pharmalink Drug Store L.L.C to distribute and commercialize its insomnia drug QUVIVIQ (daridorexant) across the UAE, Kuwait, Qatar, Oman, and Bahrain. |
| 2026 | Contracts/Agreements | In January, the company entered into an agreement with EMS S.A. to bring QUVIVIQ (daridorexant) to patients across Latin America. |
| 2025 | Regulatory Approval | In September, the company received approval from Swissmedic for JERAYGO (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products. |
Competitor Comparison
| Key Parameters | Idorsia Pharmaceutical Ltd | Kuros Biosciences AG | ADC Therapeutics SA | Adienne Pharma & Biotech SA | F. Hoffmann-La Roche Ltd |
|---|---|---|---|---|---|
| Headquarters | Switzerland | Switzerland | Switzerland | Switzerland | Switzerland |
| City | Allschwil | Schlieren | Epalinges | Lugano | Basel |
| State/Province | Basel-Landschaft | Zurich | - | Tessin | - |
| No. of Employees | 500 | 178 | 188 | - | - |
| Entity Type | Private | Public | Public | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jean Paul Clozel | Chairman | Executive Board | 2024 | 70 |
| Mathieu Simon | Vice Chairman | Executive Board | 2020 | 69 |
| Srishti Gupta, M.D. | Chief Executive Officer; Director | Executive Board | 2025 | - |
| Amer Joseph | Chief Medical Officer; Executive Vice President; Head - Global Clinical Development | Senior Management | 2026 | - |
| Eva Caroff | Head - Chemical Sciences; Senior Vice President | Senior Management | - | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer